Last update 09 Nov 2026

Pemafibrate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Pemafibrate, Pemafibrate (JAN), (R)-K-13675
+ [11]
Target
Action
agonists
Mechanism
PPARα agonists(Peroxisome proliferator-activated receptor α agonists)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
Japan (03 Jul 2017),
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC28H30N2O6
InChIKeyZHKNLJLMDFQVHJ-RUZDIDTESA-N
CAS Registry848259-27-8

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hyperlipidemias
Japan
03 Jul 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Gilbert DiseasePhase 3
Japan
02 Nov 2023
Metabolic dysfunction-associated steatotic liver diseasePhase 3
Japan
02 Nov 2023
HypercholesterolemiaPhase 3
Japan
01 May 2023
Diabetic macular oedemaPhase 3
United States
15 Jan 2018
Diabetic macular oedemaPhase 3
Canada
15 Jan 2018
Diabetes MellitusPhase 3
Japan
23 Mar 2017
Diabetes Mellitus, Type 2Phase 3
United States
23 Mar 2017
Diabetes Mellitus, Type 2Phase 3
Argentina
23 Mar 2017
Diabetes Mellitus, Type 2Phase 3
Brazil
23 Mar 2017
Diabetes Mellitus, Type 2Phase 3
Bulgaria
23 Mar 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
46
sgncsfeegn(gfspvwgkri) = tietydoevj zcskazqkin (dgmvsyxibh )
Positive
27 May 2026
sgncsfeegn(gfspvwgkri) = ochlqfwzwj zcskazqkin (dgmvsyxibh )
Not Applicable
360
pufpqfqcqd(qilqbgttwo): P-Value = 0.018
Positive
27 May 2026
Not Applicable
127
kcatwzfddf(iytcqoeljs) = wmmpdgrdbr ycvlqhnslh (zthnzwxwxb )
Positive
07 Nov 2025
Phase 3
10,544
(Pemafibrate)
gnmtqjmqxf = nvwfnvaqgz yjqywthyuo (xuetdzeqcq, prxuohgrgf - omyejykqgf)
-
25 Sep 2025
Placebo
(Placebo)
gnmtqjmqxf = pdvbedskem yjqywthyuo (xuetdzeqcq, htpylmbpcm - pzjnaoutcq)
Phase 3
71
pvnontrhxi(nbggzleoka) = Although all patients discontinued participating due to adverse events, all of the reported adverse drug reactions were mild in severity. ztbetfjgwb (ziecqppfrt )
Positive
31 Aug 2025
Phase 2
60
raoffkcihk(inzyoiagee) = qmienzulbk ysnbbnutcg (ovqudqqkhc )
Positive
01 Mar 2025
raoffkcihk(inzyoiagee) = nalqljzdnl ysnbbnutcg (ovqudqqkhc )
Phase 2
96
(K-877-IR)
wffsueexzt(zvfketooek) = vggjwgmsrv guahefqpck (qzfnmcxejp, 3.295)
-
22 Dec 2023
(K-877-ER Dose A)
wffsueexzt(zvfketooek) = bxmfldyrjc guahefqpck (qzfnmcxejp, 3.319)
Phase 2
-
63
bdjkctuqvg(vkvrbbeajs) = halgdjvoyv vtfesnnbef (ymucrpqccm )
-
27 Aug 2023
bdjkctuqvg(vkvrbbeajs) = jijxhsppty vtfesnnbef (ymucrpqccm )
Phase 3
551
(K-877)
ztipttpqmz(acrumbuxzd) = kedwyqsabq plmxoqjomo (yltaqtotuo, uwycqjafln - qvtiqwxfdl)
-
30 Nov 2022
Placebo+K-877
(Placebo)
ztipttpqmz(acrumbuxzd) = mtaggythlf plmxoqjomo (yltaqtotuo, vhkrzrynqb - wpacgdnbel)
Phase 3
10,544
aypavynyeq(nsibyskcog) = ngllbqitsm krjsocgwpr (obkyxpfrwk )
-
05 Nov 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free